Ceprotin: Withdrawal of the application to change the marketing authorisation

human protein C


On 22 October 2014, Baxter AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Ceprotin to treat acquired protein C deficiency.

  • List item

    Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Ceprotin (human protein C) (PDF/86.65 KB)

    First published: 21/11/2014
    Last updated: 21/11/2014

  • Key facts

    Product number
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    International non-proprietary name (INN) or common name
    • human protein C
    Active substance
    • human protein C
    Date of withdrawal
    Company making the application
    Takeda Manufacturing Austria AG
    Withdrawal type

    All documents

    Related content

    Related information on withdrawals

    The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

    How useful was this page?

    Add your rating